Orasis Pharmaceuticals
Dr. Berdahl is a board-certified ophthalmologist practicing in Sioux Falls, South Dakota. He is widely regarded as one of the leading international cataract surgeons. Dr. Berdahl is one of the very few surgeons in the United States who is also fellowship trained in cornea, glaucoma, and refractive surgery. He has performed more than 25,000 eye surgeries around the globe so far. His published work has primarily focused on the fundamental causes of glaucoma, minimally invasive glaucoma surgery, and astigmatism management, during and after cataract surgery. Dr. Berdahl has been involved in numerous FDA monitored clinical trials on some of the most exciting technologies in ophthalmology. He founded Equinox, which is developing the first non-surgical, non-pharmacologic way to lower eye pressure for glaucoma treatment. He co-invented the MKO melt, which provided sedation during cataract surgery without the use of an IV. Additionally, he created astigmatismfix.com to help thousands of surgeons fix residual astigmatism after cataract surgery. In an effort to improve access to care, he also co-founded ExpertOpinion.MD, which provides opinions online to patients from prominent doctors around the world.
Dr. Berdahl completed his fellowship at Minnesota Eye Consultants. Prior to the fellowship, he completed his residency at Duke University and an internship at the Mayo Clinic in Scottsdale, Arizona. Dr. Berdahl received his medical degree from the Mayo Medical School in Rochester, Minnesota and a Bachelor of Science in physics from Augustana College in Sioux Falls, South Dakota.
This person is not in the org chart
This person is not in any offices
Orasis Pharmaceuticals
2 followers
Orasis is an emerging ophthalmic pharmaceutical company with the goal of making near vision clear again. They are committed to the Ophthalmology and Optometry segments because they know that presbyopia is ubiquitous. By virtue of their first in class formulation, Orasis is well-positioned to be first-line therapy in this emerging category by addressing a significant unmet need for patients.